| Publications by Biophoenix' Principals |
| European Market for Hormone-Related Tests | |
|---|---|
 | |
| Publisher: | Frost & Sullivan Inc |
| Year of publication: | 1991 |
| Type of publication: | Market report |
| Publisher's reference (if any): | E1480 |
| Author(s): | Sreten Bogdanovic |
| Approximate page count: | 300 |
| Price when published: | $3,400 |
Remarks:
| |
EUROPEAN MARKET FOR
HORMONE-RELATED TESTS
FROST & SULLIVAN INC., E1480
FEBRUARY 1991
TABLE OF CONTENTS
Chapter or Section Page
TABLE OF CONTENTS TOC 1
EXECUTIVE SUMMARY ES 1
CHAPTER 1
INTRODUCTION, SCOPE, METHODOLOGY, AND DEFINITIONS
1.1 Introduction 1.1
1.1.1 Hormones and their Measurement 1.1
1.1.2 How Are Hormones Measured? 1.2
1.1.3 Origins and Growth of the
Endocrinology Market 1.3
1.2 Objectives and Scope of this Report 1.7
1.2.1 Major Objectives 1.7
1.2.2 Scope of the Report 1.9
1.2.3 Report Summary 1.11
1.3 Research Methodology 1.16
1.4 Abbreviations and Definitions 1.17
1.5 Exchange Rates Used in Compiling this Report 1.23
CHAPTER 2
ESSENTIALS OF ENDOCRINOLOGY AND HORMONE ASSAY
2.1 Analytical Approaches to Hormone Assay 2.1
2.1.1 Introduction 2.1
2.1.2 Immunoassays 2.1
2.1.3 Chromatography 2.3
2.1.4 Mass Spectrometry 2.4
2.1.5 Bioassay 2.5
2.1.6 Miscellaneous Chemical Tests 2.5
2.1.7 Inspection of Tissue Morphology 2.6
2.2 Laboratory Investigations in Endocrinology 2.7
2.2.1 Assay of Basal Hormone Levels 2.7
2.2.2 Stimulation and Suppression Tests 2.8
2.2.2.1 Feedback Control of Hormone Secretion 2.8
2.2.2.2 Receptors and Hormone Responsiveness 2.8
2.2.2.3 Use of Stimulation and Suppression
Tests 2.9
2.2.3 Histochemistry 2.10
2.2.4 Immunoassay Methodologies 2.10
2.2.4.1 General Characteristics of
Immunoassays 2.10
2.2.4.2 Antigens and Antibodies 2.11
2.2.4.3 Labelling 2.11
2.2.4.4 Bound-Free Separation 2.12
2.2.4.5 Competitive Immunoassays 2.12
2.2.4.6 Other Competitive Binding Assays 2.13
2.2.4.7 Immunometric Immunoassays 2.14
2.2.4.8 Homogeneous Immunoassays 2.16
2.2.4.10 Monoclonal Antibodies 2.17
2.2.4.10.1 Comparison with Polyclonal
Antibodies 2.17
2.2.4.10.2 Production of Monoclonal
Antibodies 2.18
2.2.4.11 Standardisation of Immunoassays 2.19
2.2.4.12 Matrix Effects 2.20
2.2.4.13 Sensitivities and Detection Limits 2.21
2.3 Aspects of Clinical Endocrinology 2.23
2.3.1 Chemical Diversity of Hormones 2.23
2.3.2 Effects of Hormones 2.23
2.3.3 Mode of Action of Hormones 2.24
2.3.4 Factors Affecting in vivo Hormone
Activity 2.24
2.4 Thyroid-Related Disorders 2.26
2.4.1 Introduction 2.26
2.4.2 Overview of Thyroid Disease 2.27
2.4.3 Hypothyroidism 2.27
2.4.3.1 Hypothyroidism in Adults 2.27
2.4.3.2 Neonatal Hypothyroidism 2.28
2.4.4 Hyperthyroidism 2.29
2.4.4.1 Causes of Hyperthyroidism 2.29
2.4.4.2 Graves' Disease 2.30
2.4.4.3 Treatment of Hyperthyoidism 2.30
2.4.5 Goitres and Thyroid Autoimmunity 2.31
2.4.5.1 Goitre and its Causes 2.31
2.4.5.2 Thyroid Autoimmunity 2.32
2.4.5.3 Treatment of Goitres and Thyroid
Autoimmunity 2.33
2.5 Disorders of the Reproductive System 2.33
2.5.1 Overview of Female Reproductive
Endocrinology 2.33
2.5.2 The Menstrual Cycle 2.34
2.5.2.1 Follicular Phase 2.34
2.5.2.2 Luteal Phase 2.35
2.5.3 Overview of Ovarian Dysfunction 2.36
2.5.4 Hirsuitism and Virilism 2.38
2.5.4.1 Introduction 2.38
2.5.4.2 Causes of Hirsuitism and Virilism 2.39
2.5.4.3 Treatment of Hirsuitism and
Virilism 2.40
2.5.5 Infertility 2.41
2.5.5.1 Prevalence and Causes of Infertility 2.41
2.5.5.2 Treatment of Infertility 2.42
2.5.6 Pregnancy 2.43
2.5.7 Overview of Male Reproductive
Endocrinology 2.45
2.5.7.1 Testicular Function 2.45
2.5.7.2 Sexual Maturation in Males 2.46
2.5.8 Overview of Male Sexual Dysfunction 2.47
2.5.8.1 Introduction 2.47
2.5.8.2 Infertility 2.47
2.5.8.3 Developmental Abnormalities 2.48
2.5.8.4 Testicular Injury 2.49
2.5.8.5 Testicular Tumours 2.50
2.6 Disorders of Calcium Homoeostasis 2.50
2.6.1 Introduction 2.50
2.6.2 Hyperparathyroidism and Hypercalcaemia 2.51
2.6.3 Hypoparathyroidism and Hypocalcaemia 2.52
2.6.4 Rickets and Osteomalacia 2.52
2.6.5 Osteoporosis 2.53
2.7 Disorders of Growth 2.54
2.7.1 Introduction 2.54
2.7.2 Acromegaly and Gigantism 2.54
2.7.3 Pituitary Dwarfism 2.55
2.8 Diabetes and Related Disorders 2.56
2.8.1 Introduction 2.56
2.8.2 Diabetes Mellitus 2.57
2.8.3 Nondiabetic Hypoglycaemia 2.57
2.8.4 Neonatal Hypoglycaemia 2.58
2.9 Adrenocortical Dysfunction 2.59
2.9.1 The Adrenal Cortex 2.59
2.9.2 Cushing's Syndrome 2.60
2.9.3 Addison's Disease 2.61
2.9.4 Primary Aldosteronism 2.62
2.9.5 Secondary Aldosteronism 2.62
2.10 Hormone-Secreting Tumours 2.63
2.10.1 Introduction 2.63
2.10.2 Evaluation of Hormone-Secreting
Tumours 2.63
2.10.2.1 Assessment of Tumour
Differentiation 2.63
2.10.2.2 Biochemical Grading and Staging
of Tumours 2.64
2.10.3 General Features of Endocrine Tumours 2.65
2.10.4 Survey of Specific Hormone-Secreting
Tumours 2.66
2.10.4.1 Pituitary Tumours 2.66
2.10.4.2 Pancreatic Tumours 2.67
2.10.4.3 The Carcinoid Syndrome and
Carcinoid Tumours 2.68
2.10.4.4 Multiple Endocrine Neoplasia 2.69
2.10.4.5 Vasopressinomas 2.70
2.10.4.6 Prevalence of Hormone Secretion
in Tumours 2.72
2.10.5 Treatment of Hormone-Sensitive Tumours 2.72
CHAPTER 3
SURVEY OF HORMONE-RELATED ASSAY PRODUCTS
3.1 Introduction 3.1
3.2 Commercial Immunoassays 3.1
3.2.1 Product Presentation 3.1
3.2.2 Commercial Bound Label/Free Label
Separation Methods 3.2
3.2.3 Commercial Assay Configurations 3.4
3.2.4 Commercial Radioimmunoassays 3.5
3.2.5 Commercial Enzyme Immunoassays 3.6
3.2.6 Commercial Fluoroimmunoassays 3.7
3.2.7 Commercial Luminescent Immunoassays 3.9
3.2.8 Automation of Commercial
Immunoassay Systems 3.9
3.2.9 Open vs Closed Commercial
Immunoassay Systems 3.10
3.3 Thyroid Function Tests 3.11
3.3.1 T3 and T4 3.11
3.3.2 Thyroid-Stimulating Hormone (TSH) 3.11
3.3.3 Measurement of Thyroid-related Hormones 3.12
3.3.3.1 Introduction 3.12
3.3.3.2 Assay of Total Thyroid Hormones 3.12
3.3.3.2.1 Thyroid Hormone Binding
Proteins 3.12
3.3.3.2.2 Binding Proteins and
Serum Hormone Levels 3.13
3.3.3.2.3 Thyroid Hormone Binding
Capacity 3.14
3.3.3.3 Direct Assay of Free Thyroid
Hormones 3.15
3.3.3.3.1 Equilibrium Dialysis 3.15
3.3.3.3.2 Labelled Analogue
Immunoassays 3.16
3.3.3.3.3 Back-Titration (Two-Step)
Immunoassays 3.16
3.3.3.3.4 Solid Phase Antigen
Immunoassays 3.17
3.3.3.3.5 Commercial Free Thyroid
Hormone Assays 3.17
3.3.3.3.6 The TSH Stimulation Test 3.20
3.3.3.4 Measurement of TSH 3.20
3.3.3.4.1 Measurement of TSH in Adults 3.20
3.3.3.4.2 Measurement of TSH in Neonates 3.21
3.3.3.4.3 The TRH Test 3.21
3.3.4 In vivo Radioisotope Scanning 3.22
3.3.5 Ultrasound and X-ray Scanning 3.23
3.3.6 Antithyroid Antibodies 3.24
3.3.6.1 Antithyroglobulin Antibodies 3.24
3.3.6.2 Thyroid Microsomal Antibodies 3.24
3.3.6.3 Thyroid-Stimulating Antibodies 3.25
3.3.7 Monitoring T4 Replacement Therapy 3.26
3.3.8 Biochemical Thyroid Screening
Strategies 3.26
3.4 Tests of Reproductive Function 3.28
3.4.1 Gonadotrophins 3.28
3.4.2 Ovarian Hormones 3.28
3.4.3 Inhibin 3.30
3.4.4 Investigation of Female
Reproductive Disorders 3.30
3.4.4.1 Introduction 3.30
3.4.4.2 Investigation of Amenorrhoea 3.31
3.4.4.3 Investigation of Hirsuitism
and Virilism 3.32
3.4.4.4 Evaluation and Treatment of
Infertility 3.35
3.4.4.5 Ovulation Test Kits 3.36
3.4.5 Pregnancy-associated Hormones 3.36
3.4.5.1 Human Chorionic Gonadotrophin (hCG) 3.36
3.4.5.2 Oestriol and Foetal Monitoring 3.37
3.4.5.3 Human Placental Lactogen (hPL) 3.37
3.4.5.4 Prolactin 3.38
3.4.5.5 Other Pregnancy-associated Analytes 3.39
3.4.6 Investigation of Male
Reproductive Disorders 3.39
3.4.6.1 Testosterone and
Dihydrotestosterone 3.39
3.4.6.2 Investigation of Male
Sexual Dysfunction 3.40
3.5 Endocrine Tests of Calcium Homoeostasis 3.42
3.5.1 Parathyroid Hormone 3.42
3.5.2 1,25-dihydroxyvitamin D3 3.43
3.5.3 Calcitonin 3.44
3.5.4 Osteocalcin 3.45
3.5.5 Diagnosis of Hyperparathyroidism 3.45
3.5.6 Diagnosis of Hypoparathyroidism 3.47
3.6 Tests in the Management of Growth Disorders 3.47
3.6.1 Growth Hormone 3.47
3.6.2 Somatomedin C 3.48
3.6.3 Diagnosis of Acromegaly and Gigantism 3.49
3.6.4 Early Diagnosis of Pituitary Dwarfism 3.49
3.7 Diabetes-Related Tests 3.50
3.7.1 Insulin, Proinsulin, and C-peptide 3.50
3.7.2 Biochemical Diagnosis of Diabetes 3.51
3.7.2.1 Basal Glucose Concentration 3.51
3.7.2.2 Oral Glucose Tolerance Test 3.52
3.7.3 Biochemical Management of Diabetes 3.52
3.7.3.1 Choice of Diabetic Therapy 3.52
3.7.3.2 Monitoring Insulin Replacement
Therapy 3.53
3.7.3.3 Assessment of Long-Term Control 3.54
3.7.4 Evaluation of Nondiabetic Hypoglycaemia 3.54
3.8 Tests of Adrenocortical Function 3.56
3.8.1 Adrenocorticotrophic Hormone (ACTH) 3.56
3.8.2 Adrenal Cortical Steroids 3.57
3.8.3 Measurement of Adrenal Steroids 3.58
3.8.4 Clinical Significance of Serum
Cortisol Levels 3.59
3.8.5 Diagnosis of Cushing's Syndrome 3.60
3.8.5.1 Urinary Free Cortisol 3.60
3.8.5.2 Dexamethasone Suppression Tests 3.60
3.8.5.3 Insulin Tolerance Test 3.61
3.8.5.4 Basal and Stimulated Serum ACTH 3.61
3.8.6 Diagnosis of Addison's Disease 3.62
3.8.7 Therapy Monitoring in Addison's Disease 3.62
3.8.8 Aldosterone, Renin, and Angiotensin 3.63
3.8.8.1 Introduction 3.63
3.8.8.2 Laboratory Investigations in
Aldosteronism 3.64
3.9 Hormone Tests and Cancer 3.66
3.9.1 Serotonin, HIAA, NSE, and Carcinoid
Tumours 3.66
3.9.2 Calcitonin and Multiple Endocrine
Neoplasia 3.66
3.9.3 VIP 3.67
3.9.4 Insulin 3.68
3.9.5 Glucagon and Somatostatin 3.68
3.9.6 Pancreatic Polypeptide 3.69
3.9.7 Gastrin 3.69
3.9.8 Vasopressin 3.70
3.9.9 hCG 3.71
3.9.10 Hormone Receptor Assays 3.72
3.9.10.1 Radioreceptor Assays 3.72
3.9.10.2 Immunoassays and
Immunohistochemistry 3.73
3.9.10.3 Receptor Assays in the Management
of Breast Cancer 3.73
3.10 Notes to Tables 3.1 and 3.2 3.75
CHAPTER 4
NATIONAL AND END-USER MARKETS
4.1 Introduction 4.1
4.2 Overview of Hormone-Related Assay End-Users 4.1
4.3 Belgium 4.3
4.3.1 Introduction 4.3
4.3.2 Health Service Structure 4.4
4.3.3 Clinical Laboratories 4.5
4.4 France 4.6
4.4.1 Introduction 4.6
4.4.2 Health Service Structure 4.8
4.4.3 Clinical Laboratories 4.8
4.5 Italy 4.10
4.5.1 Introduction 4.10
4.5.2 Health Service Structure 4.12
4.5.3 Clinical Laboratories 4.13
4.6 The Netherlands 4.15
4.6.1 Introduction 4.15
4.6.2 Health Service Structure 4.16
4.6.3 Clinical Laboratories 4.17
4.7 Spain 4.19
4.7.1 Introduction 4.19
4.7.2 Health Service Structure 4.20
4.7.3 Clinical Laboratories 4.21
4.8 United Kingdom 4.23
4.8.1 Introduction 4.23
4.8.2 Health Service Structure 4.27
4.8.3 Clinical Laboratories 4.27
4.9 West Germany 4.29
4.9.1 Introduction 4.29
4.9.2 Health Service Structure 4.31
4.9.3 Clinical Laboratories 4.32
4.10 Demographic Data 4.34
CHAPTER 5
MARKET ANALYSES AND FORECASTS
5.1 Introduction 5.1
5.1.1 Scope of this Chapter 5.1
5.1.2 Laboratory Immunoassays 5.2
5.1.3 Pregnancy and Ovulation Tests 5.3
5.1.4 Rapid Glucose Tests 5.3
5.2 Laboratory Immunodiagnostics 5.4
5.2.1 Overall Market Characteristics 5.4
5.2.2 Manufacturers 5.6
5.2.3 Forecasts 5.7
5.2.3.1 Thyroid Function Tests 5.7
5.2.3.2 Reproductive Endocrinology 5.9
5.2.3.3 Metabolic Endocrinology 5.10
5.2.3.4 Hormone-Related Tests in Oncology 5.11
5.3 Pregnancy and Ovulation Tests 5.12
5.3.1 Manufacturers 5.12
5.3.2 Forecasts 5.13
5.4 Blood Glucose Monitoring 5.14
5.4.1 Manufacturers 5.14
5.4.2 Forecasts 5.15
5.5 Urinary Glucose Monitoring 5.15
5.5.1 Manufacturers 5.15
5.5.2 Forecasts 5.16
CHAPTER 6
SUPPLIER PROFILES
6.1 Introduction 6.1
6.2 Abbott Laboratories 6.2
6.3 Amersham International PLC 6.5
6.4 Ares-Serono Group 6.9
6.5 Baxter 6.12
6.6 Becton Dickinson 6.14
6.7 Behring 6.16
6.8 bioMerieux 6.17
6.9 Bio-Rad Laboratories 6.18
6.10 Boehringer Mannheim GmbH 6.20
6.11 Ciba-Corning Diagnostics 6.23
6.12 CIS Bioindustries 6.24
6.13 Diagnostic Products Corporation 6.25
6.14 Diagnostics Pasteur 6.26
6.15 E.I. Du Pont de Nemours & Company 6.26
6.16 Euro-Diagnostics 6.28
6.17 Hybritech 6.30
6.18 Immunodiagnostic Systems 6.35
6.19 Novo-Nordisk 6.37
6.20 Pharmacia-LKB 6.39
6.21 Roche 6.43
6.22 Sangtec-Mallinckrodt 6.45
6.23 Sorin Biomedica 6.47
CHAPTER 7
TRENDS, OPPORTUNITIES, AND PROSPECTS
7.1 Product and Market Trends 7.1
7.1.1 The Switch from RIA 7.1
7.1.2 Thyroid Function Tests 7.2
7.1.3 Reproductive Endocrinology 7.2
7.1.4 Diabetes Monitoring 7.3
7.2 Product and Market Opportunities 7.3
7.2.1 What Type of System? 7.3
7.2.2 Which Analytes? 7.5
7.2.2.1 Introduction 7.5
7.2.2.2 Thyroid Function 7.6
7.2.2.3 Reproductive Function 7.8
7.2.2.4 Metabolic Endocrinology 7.9
7.2.2.5 Endocrine Oncology 7.10
7.2.2.6 The Highest-Volume Analytes 7.10
7.2.3 Which Assay Format? 7.12
7.2.3.1 Choice of Solid Phase 7.12
7.2.3.2 Self-Contained Cartridge Systems 7.12
7.2.3.3 Antibody Configuration 7.13
7.2.3.4 General Features of the Assay 7.14
7.2.4 Which Label? 7.15
7.2.5 Pregnancy and Ovulation Tests 7.15
7.2.6 Diabetes Monitoring 7.16
7.3 Prospects for Hormone-Related Tests 7.17
APPENDIX 1
SCHEDULE OF TRADE AND PROFESSIONAL ASSOCIATIONS
A1.1 Trade Asociations A1.1
A1.2 Professional Associations A1.2
APPENDIX 2
JOURNALS AND NEWSLETTERS A2.1
APPENDIX 3
SCHEDULE OF COMPANIES MENTIONED A3.1
LIST OF TABLES
TABLE ES 1
MAJOR ANALYTES COVERED IN THIS REPORT ES 14
TABLE ES 2
THE LEADING HORMONE-RELATED ANALYTES ES 17
TABLE ES 3
THE LEADING MANUFACTURERS OF HORMONE-RELATED TESTS ES 18
TABLE ES 4
HORMONE-RELATED TESTS IN 1989: MARKET BY COUNTRY
AND PRODUCT GROUP ES 19
TABLE ES 5
HORMONE-RELATED TESTS: SALES IN 1989 AND 1995 ES 20
TABLE ES 6
HORMONE-RELATED TESTS: MARKET STRUCTURE IN 1989
AND 1995 ES 21
TABLE 3.1
HORMONE-RELATED TESTS BY ANALYTE AND APPLICATIONS
GROUP 3.77
TABLE 3.2
HORMONE-RELATED TESTS BY MANUFACTURER 3.101
TABLE 4.1
HOSPITALS AND LABORATORIES IN BELGIUM 4.6
TABLE 4.2
HOSPITALS AND LABORATORIES IN FRANCE 4.9
TABLE 4.3
HOSPITALS AND LABORATORIES IN ITALY 4.13
TABLE 4.4
HOSPITALS AND LABORATORIES IN THE NETHERLANDS 4.18
TABLE 4.5
HOSPITALS AND LABORATORIES IN SPAIN 4.22
TABLE 4.6
HOSPITALS AND LABORATORIES IN THE UNITED KINGDOM 4.28
TABLE 4.7
HOSPITALS AND LABORATORIES IN WEST GERMANY 4.33
TABLE 4.8
GENERAL DATA ON THE COUNTRIES SURVEYED IN
THIS REPORT 4.36
TABLE 5.1
LEADING COMPANIES IN ENDOCRINOLOGY DIAGNOSTICS 5.17
TABLE 5.2
TSH ASSAY SALES IN 1989, AND FORECASTS TO 1995 5.19
TABLE 5.3
TOTAL T4 ASSAY SALES IN 1989, AND FORECASTS TO 1995 5.20
TABLE 5.4
FREE T4 ASSAY SALES IN 1989, AND FORECASTS TO 1995 5.21
TABLE 5.5
TOTAL T3 ASSAY SALES IN 1989, AND FORECASTS TO 1995 5.22
TABLE 5.6
FREE T3 ASSAY SALES IN 1989, AND FORECASTS TO 1995 5.23
TABLE 5.7
OTHER THYROID ASSAY SALES IN 1989, AND FORECASTS
TO 1995 5.24
TABLE 5.8
LH ASSAY SALES IN 1989, AND FORECASTS TO 1995 5.25
TABLE 5.9
FSH ASSAY SALES IN 1989, AND FORECASTS TO 1995 5.26
TABLE 5.10
PROLACTIN ASSAY SALES IN 1989, AND FORECASTS TO 1995 5.27
TABLE 5.11
QUANTITATIVE hCG ASSAY SALES IN 1989, AND FORECASTS
TO 1995 5.28
TABLE 5.12
hPL ASSAY SALES IN 1989, AND FORECASTS TO 1995 5.29
TABLE 5.13
OESTRADIOL ASSAY SALES IN 1989, AND FORECASTS
TO 1995 5.30
TABLE 5.14
OESTRIOL ASSAY SALES IN 1989, AND FORECASTS TO 1995 5.31
TABLE 5.15
PROGESTERONE ASSAY SALES IN 1989, AND FORECASTS
TO 1995 5.32
TABLE 5.16
TESTOSTERONE ASSAY SALES IN 1989, AND FORECASTS
TO 1995 5.33
TABLE 5.17
OTHER REPROD. HORMONE ASSAY SALES IN 1989, AND
FORECASTS TO 1995 5.34
TABLE 5.18
CALCITONIN ASSAY SALES IN 1989, AND FORECASTS
TO 1995 5.35
TABLE 5.19
CORTISOL ASSAY SALES IN 1989, AND FORECASTS TO 1995 5.36
TABLE 5.20
hGH ASSAY SALES IN 1989, AND FORECASTS TO 1995 5.37
TABLE 5.21
INSULIN ASSAY SALES IN 1989, AND FORECASTS TO 1995 5.38
TABLE 5.22
PTH ASSAY SALES IN 1989, AND FORECASTS TO 1995 5.39
TABLE 5.23
OTHER METAB. HORMONE ASSAY SALES IN 1989, AND
FORECASTS TO 1995 5.40
TABLE 5.24
ONCOLOGY ASSAY SALES IN 1989, AND FORECASTS
TO 1995 5.41
TABLE 5.25
PREGNANCY & OVULATION TEST SALES IN 1989, AND
FORECASTS TO 1995 5.42
TABLE 5.26
BLOOD GLUCOSE TEST SALES IN 1989, AND FORECASTS
TO 1995 5.43
TABLE 5.27
URINARY GLUCOSE TEST SALES IN 1989, AND
FORECASTS TO 1995 5.44
TABLE 5.28
HORMONE-RELATED TESTS: SALES IN 1989 AND 1995 5.45
TABLE 5.29
HORMONE-RELATED TESTS: MARKET STRUCTURE
IN 1989 AND 1995 5.46
TABLE 5.30
HORMONE-RELATED TESTS IN 1989: MARKET BY COUNTRY
AND PRODUCT GROUP 5.47
TABLE 5.31
HORMONE-RELATED TESTS IN 1995: MARKET BY COUNTRY
AND PRODUCT GROUP 5.48
TABLE 7.1
THE 10 HIGHEST-VOLUME ENDOCRINE IMMUNOASSAY
ANALYTES 7.11
LIST OF FIGURES
FIGURE ES 1
THE MAJOR ENDOCRINE ANALYTES IN 1989 ES 22
FIGURE ES 2
MAJOR MANUFACTURERS OF HORMONE-RELATED TESTS IN 1989 ES 23
FIGURE ES 3
EUROPEAN MARKET FOR HORMONE-RELATED TESTS
BY COUNTRY IN 1989 ES 24
FIGURE ES 4
EUROPEAN MARKET FOR HORMONE-RELATED TESTS
BY APPLICATIONS GROUP IN 1989 ES 25
FIGURE ES 5
EUROPEAN MARKET FOR HORMONE-RELATED TESTS
BY APPLICATIONS GROUP IN 1995 ES 26
FIGURE ES 6
SALES GROWTH OF MAJOR HORMONE-RELATED TESTS
BETWEEN 1989 AND 1995 ES 27
| |
